Compare GPRO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRO | AGEN |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.0M | 208.2M |
| IPO Year | 2014 | 1999 |
| Metric | GPRO | AGEN |
|---|---|---|
| Price | $0.67 | $5.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 5.4M | ★ 8.2M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.08 | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $651,542,000.00 | $42,877,086.00 |
| Revenue This Year | $23.14 | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.11 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $0.59 | $2.71 |
| 52 Week High | $3.05 | $8.70 |
| Indicator | GPRO | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 68.65 |
| Support Level | $0.59 | $3.16 |
| Resistance Level | $0.83 | $8.70 |
| Average True Range (ATR) | 0.05 | 0.77 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 7.75 | 50.00 |
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.